ContentsIssue 108 • July 2021In association withBlood plasma gets a green light in the UKAfter a 20-year ban, the UK life sciences sector has been given the go-head to produce blood plasma domestically once moreIN DEPTHA history of malaria treatmentCommentA new day for Alzheimer’s drugsBriefingIndustry newsPharma industry briefingCovid-19 briefingCommentA new day for Alzheimer’s disease treatment after FDA approvalCovid-19 vaccine inequity: the debate over patent waivers intensifiesCovid-19 vaccine efficacy in adolescentsPharmacovigilance for biotechsIn DepthMalaria vaccines through the agesTightening the rules on pharma M&AThe fishy business of shark squaleneCan pharma reduce surgical scarring?Blood plasma production: OK for the UK?Can pharma keep up with mental health?In DataInside the dealDeals analysisMarket data02/24/2024 03:28:44
Comment
A new day for Alzheimer’s drugs